Contraindicated (one)pentobarbital will reduce the level or impact of lorlatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lessen the level or outcome of vinblastine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will decrease the level or effect of voriconazole by influencing hepatic enzyme CYP2C9/10 metabolism. Minor/Importance Mysterious.
pentobarbital will decrease the extent or effect of oxybutynin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unknown.
Drug dependence to barbiturates occurs from repeated administration of a barbiturate or agent with barbiturate-like impact on a ongoing foundation, frequently in amounts exceeding therapeutic dose amounts. The features of drug dependence to barbiturates consist of:
pentobarbital will decrease the extent or influence of apremilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Coadministration with robust CYP inducers results in a significant minimize of systemic exposure of apremilast, which can end in loss of efficacy
pentobarbital will decrease the level or outcome of cevimeline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will lessen the extent or effect of methadone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
fentanyl transdermal and pentobarbital both of those increase sedation. Prevent or Use Alternate Drug. Limit use to clients for whom choice treatment alternatives are insufficient
pentobarbital will decrease the level or impact of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. The efficacy of hormonal contraceptives could be reduced.
pentobarbital will minimize the extent or outcome of ramelteon by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
pentobarbital will lessen the level or result of pantoprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
Contraindicated. Coadministration of click here doravirine with a robust CYP3A inducer may decrease doravirine plasma concentrations and/or effects. Likely for loss of virologic response and achievable resistance to doravirine.
buprenorphine subdermal implant and pentobarbital each boost sedation. Stay clear of or Use Alternate Drug. Restrict use to people for whom different procedure possibilities are insufficient